BC-11 hydrobromide

Cat. No.:	HY-108447
CAS No.:	443776-49-6
Molecular Formula:	$C_8H_{12}BBrN_2O_2S$
Molecular Weight:	290.97
Target:	Ser/Thr Protease; SARS-CoV; PAI-1
Pathway:	Metabolic Enzyme/Protease; Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (429.60 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.4368 mL	17.1839 mL	34.3678 mL
	5 mM	0.6874 mL	3.4368 mL	6.8736 mL
	10 mM	0.3437 mL	1.7184 mL	3.4368 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC_{50}=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer[1][2][3].

IC_{50} & Target

IC50: 8.2 μM (uPA)[3].

REFERENCES

[1]. Moumbock AFA, et al. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry. Arch Pharm (Weinheim). 2023 Jan;356(1):e2200371.

[2]. Semina E, et al. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur J Cell Biol. 2016 Sep;95(9):295-310.

[3]. Longo A, et al. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules. 2015 May 28;20(6):9879-89.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA